Boston, MA 07/01/2014 (wallstreetpr) – The stock of Forest Oil Corporation (NYSE:FST) remains under pressure even after Sabine Oil & Gas announced its proposal to acquire the company was on course. Already down more than 36 percent since the beginning of 2014, the stock continued on a downward rally in the previous session where it lost more than 7 percent. Faced with debt and competition pressure, Forest Oil Corporation (NYSE:FST) is seeking a deal that could demonstrate value creation for its shareholders.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) now bears a 12-month price target of $8 from Wells Fargo & Co. (NYSE:WFC). The Wells Fargo positive commentary on the stock came hot on the heels of similar moves by analysts at R.W. Baird and Maxim Group, who significantly raised their price target on the stock. Maxim anchored the stock to $22 per share, up from $6. On the other hand, R.W. Baird issued $12 price target on the stock.
Perhaps in a departure from other analysts, R.W. Baird believe that Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) could be a buyout candidate based on its position in hepatitis C drug development project. It recently emerged that another bidder made an offering for Idenix Pharmaceuticals (NASDAQ:IDIX), which accepted $3.85 billion buyout offer from Merck (NYSE:MRK).
As such, R.W. Baird believes that another bid for Idenix suggest growing appetitive for hepatitis C drugs, which Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has and positions it well for acquisition. R.W. Baird also believes that the company will be better off with a buyout deal given that its development of oral hepatitis C treatment diminish amid competition from bigger rivals.
The company suffered a bigger loss in the latest quarter than Wall Street expected at $0.17 against $0.16.
Companhia Energetica Minas Gerais (ADR) (NYSE:CIG), a Brazil-based company in the electricity sector, is expected to provide its financial report next month on August 14. The company last reported earnings in May during which it declared nearly 30 and 33 percent surge in 1Q revenue and profit, respectively. The stock carries a Buy rating from Goldman Sachs.
